Pear Therapeutics' reSET-O, a prescription app for treating opioid use disorder, may lower patients’ health care costs, compared with patients who don’t use the app, according to a study published in ...

Serve You Rx teams with Pear to lead access to prescription digital therapeutics (PDTs) with proven outcomes in treating substance use disorder (SUD) and opioid use disorder (OUD) and to support ...

Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years compared with normal treatment alone. Treatment as usual was ...

Real-world observational analysis evaluating treatment of substance use disorder (SUD) with prescription digital therapeutics (PDTs) among a large, geographically diverse population Results ...

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and ...

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...

HOLZKIRCHEN, December 10, 2018 - Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that the U.S. Food and Drug ...

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...